Eli Lilly and Company (NYSE:LLY) achieved a significant milestone in the competitive metabolic health market as its once-daily oral medication, Foundayo (orforglipron), became available in U.S. retail pharmacies on April 9, 2026.
The launch follows a landmark FDA approval granted on April 1, marking the first time a non-injectable, non-peptide GLP-1 receptor agonist has been cleared for chronic weight management.
Foundayo is indicated for adults with obesity or those who are overweight with at least one weight-related comorbid condition.
Unlike current market leaders that require weekly injections, Foundayo offers a convenient oral delivery system, a shift that analysts expect will significantly expand the patient pool by removing the "needle barrier" for many consumers.
The FDA’s decision was underpinned by data from the pivotal ATTAIN-1 Phase 3 clinical trial.
In the study, participants taking the highest dose of orforglipron achieved an average weight reduction of 27.3 pounds—or 12.4% of their body weight—over the course of the trial.
These results positioned Foundayo as a potent alternative to existing therapies, particularly for patients seeking a more flexible administration schedule.